

Panax Notoginseng Saponins: A Review of its Mechanisms of Antidepressant or Anxiolytic Effects and Network Analysis on Phytochemistry and Pharmacology

Weijie Xie ^{1,2,3,4}, Xiangbao Meng ^{1,2,3,4}, Yadong Zhai ^{1,2,3,4}, Ping Zhou ^{1,2,3,4}, Tianyuan Ye ^{1,2,3,4}, Zhen Wang ^{1,2,3,4}, Guibo Sun ^{1,2,3,4}*, and Xiaobo Sun ^{1,2,3,4}*

- 1 Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China; ginseng123@163.com (W. X.); xbmeng@implad.ac.cn (X. M.); zydmailbox@163.com (Y. Z.); zhoup0520@163.com (P. Z.); yetianyuan2013@163.com (T. Y.); 15128475758@163.com (Z. W.)
- 2 Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing 100193, China
- 3 Key Laboratory of Efficacy Evaluation of Chinese Medicine against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Beijing 100193, China
- 4 Zhongguancun Open Laboratory of the Research and Development of Natural Medicine and Health Products, Beijing 100193, China

* Correspondence: sunguibo@126.com (G.S.); sun_xiaobo163@163.com (X.S.); Tel.: +86-10-5783-3220 (G.S.); +86-10-5783-3013 (X.S.)

Abstract

Panax notoginseng, as traditional Chinese medicine, has a long history of high clinical value, such as anti-inflammatory, anti-oxidation, inhibition of platelet aggregation, regulation of blood glucose and blood pressure, inhibition of neuronal apoptosis and neuronal protection, and its main ingredients are *Panax notoginseng* saponins (PNS). Currently, *Panax notoginseng* may improve mental function, have anti-insomnia and anti-depression effects, alleviate anxiety, and decrease

neural network excitation. However, the underlying effects and the mechanisms of *Panax notoginseng* and its containing chemical constituents (PNS) on these depression-related or anxiety-related diseases has not been completely established. This review summarized the antidepressant or anxiolytic effects and mechanisms of PNS, and analyzed network targets of antidepressant or anxiolytic actions with network pharmacology tools to provide directions and references for further pharmacological studies and new ideas for clinical treatment of nervous system diseases and drug studies and development.

Keywords: antianxiety, antidepression, *panax notoginseng* saponins, network pharmacology, review

1. Introduction

Depression is a chronic and recurrent syndrome of mood disorder with significant and lasting low mood [1-4]. Clinical depressed patients are characteristic of its disproportionate, emotional depression, being not commensurate with their situation, low self-esteem, and even pessimism, including depressed mood from depression to grief. Some ones may have suicide attempts or behaviors [5, 6]; in severe cases, there may be hallucinations, delusions and other psychotic symptoms [7]. The pathogenesis and etiology of still remain unknown [8-14]. However, today's knowledge proposes multiple neuronal and hormonal systems involved in the pathophysiology of the disease. Current evidence suggests that the occurrence of depression may be related to a reduced secretion of neurotransmitters [15-17], such as dopamine (DA), norepinephrine (NE), and serotonin (5-HT), neuronal apoptosis [14, 18, 19], inflammation [20-23], intestinal flora [18] and other factors [16, 18, 24, 25]. There are currently four classes of antidepressant drugs and atypical antidepressants [25, 26]. However, these drugs have undesirable side effects, with high relapse rates and a long onset of therapeutic action. Therefore, critically important is the development of efficient and safe drugs for the treatment of depression.

Panax notoginseng (Burk) F.H. Chen (*Araliaceae*) (PN) is a commonly used Chinese medicine, the root of which (Sanqi in Chinese) has been used for the treatment of hemoptysis, hemostatic, and hematoma in China and other Asian countries for its hemostatic and cardiovascular effects for more than several hundreds of years [26-28]. To the best of our knowledge, over 200 chemical constituents have been isolated from *Panax notoginseng*, but the main ingredients are *Panax notoginseng* saponins (PNS) [29], being classified into four types: protopanaxadiol, protopanaxatriol, ocotillo-type, and oleanolic acid constituents. And there are others reported to be flavonoids, cyclopeptides, saccharides and inorganic elements [30]. Pharmacological studies have shown that *notoginseng* and its extracts have many functions, such as anti-inflammatory [16, 20, 31, 32], anti-oxidation, inhibition of platelet aggregation, regulation of blood glucose [27, 33, 34], blood pressure [35-37], inhibition of neuronal apoptosis [14, 38, 39] and neuronal protection [30].

Recent studies have found that *Panax notoginseng* saponins (PNS) have good preventive and therapeutic effects on neurological diseases of the brain [28], especially in antidepressant [26-28] and anti-anxiety effects [25, 28, 40]. The preliminary determination was that anti-depressant and anti-anxiety effects may occur by increasing the levels of the brain monoamine neurotransmitters 5-hydroxytryptamine (5-HT) [41, 42] and norepinephrine (NE) in the central nervous system. Experiments also have shown that PNS modulates Na^+ currents and Ca^{2+} concentrations, increases nestin and brain-derived neurotrophic factor (BDNF) [14, 19, 29, 43-47]. Moreover, PNS or single compounds exerted antidepressant-like effects by regulating the release of interleukin (IL)-1 β , IL-6

and tumor necrosis factor (TNF)- α or anti-inflammatory cytokines IL-4 and IL-10 [10, 20, 29, 31, 32, 36, 48-56]. Such breakthroughs have been made, there is antidepressant effects on estrogen in the human body. Estrogen can act on the PI3K / Akt, MAPK / ERK and mTORC1 and other signaling pathways, and then these pathways are regulated by growth factors that protect neurons and produce estrogen-like effects on synapses. However, the role of the PNS or single compounds of PNS in normal function and in disease remains to be not much elucidated.

Therefore, this review summarized the antidepressant or anxiolytic effects and mechanisms of PNS and analyzed network targets of antidepressant or anxiolytic actions with network pharmacology tools, to provide reference for further pharmacological studies and new ideas for clinical treatment of nervous system diseases and drug studies and development.

2. Mechanisms of Antidepressant

2.1 Panax notoginseng saponins

Modern pharmacological studies have found Panax notoginseng saponins (PNS) have a good preventive and therapeutic effects of brain neurological diseases [26, 28, 57]. Ginsenosides Rg1, Rb1, Re and **notoginsenoside R1**, as the representative [26, 28, 57], showed anti-depressant and anti-anxiety activity [28, 31, 35, 58-61]. The evaluation methods of antidepressant effects include sucrose preference test (SPF) [62], forced swimming test (FST) [63-65], open field test (OFT) [62, 64, 66], elevated plus-maze (EPM) test and tail suspension test [66].

PNS (58.6%) significantly decreased immobility time in the forced swim test with little effect on locomotion in the chronic mild stress model, and significantly improved the level of animal activity and sucrose consumption [67], which may have antidepressant-like effects [45, 53, 64, 65]. Besides, when PNS was digested by Snail Enzyme to 50%, it produced the best antidepressant effects, and the main active ingredient is ginsenosides Rb1, Rb2, Rc and Rb3 [60, 68-71]. These were shown in table 1.

At present, the antidepressant mechanisms have been partly proved to be that PNS upregulates brain-derived neurotrophic factor (BDNF) expression by regulating multiple upstream neural signal transduction pathways, including AC / cAMP / PKA [45, 72], mitogen-activated protein kinase channels (TrkB / MAPK / PSK) [37, 73]; meanwhile, PNS regulates calmodulin kinase channel (Ca^{2+} / CaM / CaMK), reduces internal concentration of Ca^{2+} in nerve cells [74], and promotes the release of neurotransmitters 5-HT, NE and DA [27, 32, 41, 52]. Thereby PNS exerted its antidepressant-like effect. These were shown in table 1.

Besides, both PNS and GTS have significant antidepressant effects on LPS-induced murine CD-1 mouse models [19, 52, 53, 75] by reducing mRNA levels for IL-1 β , IL-6, TNF- α , and indoleamine 2, 3-dioxygenase (IDO) in hippocampus [52]. These were shown in table 1.

Table 1. Phytochemicals with antidepressant effect and their mechanisms of action in Panax notoginseng saponins

Name	Methods	Models	Neurobehavioral effects and Mechanisms
PNS (58.6%)	OFT; TST; FST; SPT	CMS-induced mice; CUMS-induced rats [26, 53]	↓ Immobility time in FST and TST; ↑ sucrose intake in sucrose preference test; ↑ level of animal activity; ↑ Expression of BDNF [60, 68-71].
Purified PNS	SPF; OFT	CUMS-induced SD rats	Regulate upstream neural signal transduction pathways: AC/cAMP/PKA, TrkB/MAPK/PSK and Ca^{2+} /CaM / CaMK signaling pathway; ↓ Concentration of Ca^{2+} in nerve cells; ↑ release of neurotransmitter 5-HT, DA and NE [45, 72].
PNS and GTS	FST; SPT	LPS-induced KM mice; CD-1 mice	↓ mRNA of IL-1 β , IL-6, TNF- α and IDO; ↓ Inflammation in the brain [53, 76-79].

Ginsenoside Rg1	OFT; FST; SPT	CMS and CUMS-induced depression Animal Model	↓ CMS-induced increase of corticosterone levels in serum; ↑ CUMS-induced CREB phosphorylation in the amygdala of the brain [45]; ↑ expression of BDNF [33, 43]; regulate hyperactivity of the HPA axis in depressed states; ↑ neuronal status, neurons quantity and density of dendritic spines [19, 45].
Ginsenoside Rg1	FST; SPT	CMS and CUMS-induced depression animal model	↑ Expression of connexin and gap junction of astrocytes in the prefrontal cortex of the brain; ↑ dense ultrastructure; ↓ permeability and depression-like behaviors induced by CUS in rats.
Ginsenoside Rg1	FST; SPT	Cerebral inflammatory model mice	↓ Recruitment of Ly6C (hi) monocytes in inflammatory brain model mice [16]; activate THP-1 monocytes; blocks the feedback-regulated release of CCL2 from astroglial cells; ↓ CCL2 signaling pathways: p38/MAPK and PI3K/Akt activities.
Ginsenoside Rg1	TST; FST; SPT	CUMS-induced depression rats	↓ Contents of Glu and Asp in hippocampus, ↑ contents of GABA and Tau; ↓ depression-like Behavior in CUMS model rats [15, 67]
Ginsenoside Rb1 and ginsenoside compound K	TST; FST	CUMS-induced depression rats	↑ Expression of 5-HT _{2A} R mRNA and activate of 5-HT _{2A} R [42]; the antidepressant effects of Rb1 and the metabolite ginsenoside compound K may be antagonized by 5-HT _{2A} R antagonists (Ritanerin), indicating that Rb1 has a similar 5-HT transmitter activation effect [68, 80, 81]
Ginsenoside Rg3 and ginsenoside Rh2	OFT; SPT	LPS-induced mice and CSDS-induced mice	↓ IL-6 and TNF- α in plasma and the expression of indoleamine-2, 3-dioxygenase (IDO) in brain; ↓ turnover of tryptophan and 5-HT in hippocampal tissue; regulate secretory activities of microglia and transcription of NF- κ B in nuclear; ↑ expression of BDNF; ↓ depressive behavior or symptoms [19, 27, 53, 75, 82].
Ginsenoside Rg5	OFT; FST; SPT	CSDS-induced mice	↓ Trk and AchE; ↑ expression of BDNF [69, 83].
Ginsenoside Re	OFT; TST	CMS-induced rat model	Regulate the central adrenergic system; ↓ expression of TH in the locus coeruleus area; ↓ decrease of BDNF in the hippocampus, and regulates the secretion of corticosterone from the HPA axis [44].

2.2 Single component: Rg1

Among Panax notoginseng saponins, ginsenoside Rg1, Rb1, Rc and Rb3 are as important representative components of PNS antidepressant, belonging to the original ginseng diol type saponins [25, 27, 63], and the contents of ginsenoside Rb3 and Rc were 17.66% and 9.32% respectively [25, 27, 33].

By conducting open field tests, tail suspension tests (TST), forced swimming tests (FST) or sugar consumption tests, ginsenoside Rg1 showed antidepressant effect in chronic mild stress (CMS) or chronic unpredictable mild stress (CUMS) induced animal models of Depression [45, 64, 67, 84]. Ginsenoside Rg1 significantly reversed increase of serum corticosterone induced by CMS, increased the phosphorylation of cAMP response element-binding protein (CREB) in rat cerebral amygdala induced by CUMS, up-regulated expression of BDNF in the hippocampus [32, 43, 45] and down-regulated serum corticosterone level [43]. And it regulates the hyperthyroidism of HPA axis in depression, plays a positive role in activating neurotrophic factor BDNF and protein kinase [43, 75], and also improve the neuronal status, increase the number of neurons and dendritic spine density [32, 43, 45], producing antidepressant effect.

Moreover, ginsenoside Rg1 could up-regulate the expression of connexin, improve the gap junctional connectivity of astrocytes in the prefrontal cortex, decrease the permeability, increase the ultrastructure and reduce the depression-like behavior of rats induced by CUMS [85]. As present studies found that Ly6C (hi) blood mononuclear cells can be used as anti-depressant regulatory targets [10], Rg1 selectively suppressed Ly6C hi monocytes recruitment to the inflamed mice brain [10], Rg1 pretreatment on activated THP-1 monocytes retarded their ability to trigger CCL2 secretion from co-cultured U251 MG astrocytes, and CCL2-triggered p38/MAPK and PI3K/Akt activation were blocked by Rg1 [10, 86]. Besides, Rg1 suppressed depression-like behaviors in

CUMS model rats by reducing contents of Glu and Asp in hippocampus and increasing GABA and Tau content, exerting antidepressant effects [67].

2.3 Single component: Rb1

Ginsenoside Rb1 and its metabolite (ginsenoside compound K) could activate 5-HT_{2A}R, and may also up-regulate the mRNA expression of 5-HT_{2A}R, which showed anti-depressant effects on ovariectomized rat model carried with ovariectomy, whereas the anti-depression effect of Rb1 and ginsenoside compound K may be reversed by the 5-HT_{2A}R antagonist (ritanserin), which generally indicates that Rb1 has a similar-neurotransmitter of 5-HT activation effect [42]. These were shown in table 1.

2.4 Single component: Rb3

Ginsenoside Rb3 had significant anti-immobility effects in mice in the forced swim and tail suspension tests and reduced the number of escape failures in the learned helplessness procedure by using the forced swimming test, tail suspension test and learned helplessness procedure. Biochemical variations (i.e. brain-derived neurotrophic factor and the monoamine neurotransmitters 5-hydroxytryptamine, dopamine, and norepinephrine) are mainly involved in Rb3's antidepressant-like effects [25, 27]. And using GABA_A receptor agonist muscimol was similar to that of ginsenoside Rb 3, which indicated that the activation of the GABA_A receptor is correlated with the neuroprotective mechanisms of ginsenoside Rb3 [25, 27, 87]. These were shown in table 1.

2.5 Single component: Rg3

Ginsenoside Rg3 exerted a significant antidepressant effect on LPS-induced mouse model by immunomodulatory and anti-inflammatory effects [19, 53, 75], which decreased levels of IL-6, TNF- α in plasma and indoleamine-2,3 -deoxygenases (IDO) expression in the hippocampus, reduced or inhibited the turnover of the tryptophan-serotonin (5-HT) in the hippocampus, regulated the secretory activity of microglia microglial cells and the transcription of NF- κ B in the nucleus, and repaired tryptophan-kynurenine metabolic balance, thereby weakening the depressant-like behavior or symptoms. In addition, Rg3 exerted an anti-depressant effect on chronic social defeat stress (CSDS)-induced mice model, but had no significant effect on animal activity and enhanced BDNF expression [75]. These were shown in table 1.

Besides, ginsenoside Rg5 induced antidepressant effect by inhibiting Trk, and AchE activity and upregulating BDNF expression in chronic social defeat stress (CSDS) induced model mice [83]. Ginsenoside Re regulated the central adrenergic system, inhibited tyrosine hydroxylase (TH) expression in the locus coeruleus, blocked the decrease of BDNF in hippocampus and regulated the secretion of corticosterone in the HPA axis, thus alleviating and regulating the synthesis of depression or anxiety symptoms [44]. These were shown in table 1.

3. Mechanisms of Antianxiety

At present, representatives of *Panax notoginseng*, stem and leaf soap components or part of ginsenosides that have been shown to have anxiolytic effects are ginsenoside Rb1, Re, PPD [71, 81, 88, 89], ginsenoside Rh1 [71] and ginsenoside Rg3 [27, 53, 75, 82]. In chronic mild stress (CMS) - induced rats, 1-DOPA-induced running behavior in mice or 5-HTP-induced head-twitch tests, PNS decreased immobility time, increased the levels of 5-hydroxytryptamine, dopamine, and noradrenaline, reduced basal $[Ca^{2+}]_i$ levels in cultured neurons, which were mediated by modulation of brain monoamine neurotransmitters and intracellular Ca^{2+} concentration, producing anti-anxiety and antidepressant effect [26, 28, 90]. These were shown in table 2.

Ginsenoside Rb1 reduced the anxiety index, increased the risk assessment, reduced grooming behaviors in the EPM test, and increased the total number of line crossings of an open field in single prolonged stress (SPS)-induced model and in model rats of post-traumatic stress disorder (PTSD) by increasing the expression of neuropeptide Y induced by SPS-induced decrease in hypothalamic; increase the expression of tyrosine hydroxylase in locus coeruleus and decrease the mRNA expression of BDNF in hippocampus.

At the same time, ginsenoside Rb1 and Re's intestinal metabolites PPD and compound K, ginsenoside Rh1 can increase arm opening time in EPM and reduce the serum levels of adrenone IL-6, and the role of γ -aminobutyrate-A (GABA_A) receptor (s) exert anxiolytic effects [27, 71]. Pseudoginsenoside-F(11) greatly ameliorated, the anxiety-like behaviors induced by MA, shortened MA-induced prolonged latency, decreased the error counts, significant decreases in the contents of dopamine (DA), 3,4-dihydroxyphenacetic acid (DOPAC), homovanillic acid (HVA), and 5-hydroxyindoacetic acid (5-HIAA) in the brain of MA-treated mice; partially, but significantly, antagonize MA-induced decreases of DA [91]. Ginsenoside Rg3, Rh2, Rg1 and Ro significantly increased both the frequency and duration of open arm entries, indicating that ginsenoside Rb1 is one of the active anxiolytic components [82]. These were shown in table 2.

Table 2. Phytochemicals with anxiolytic effect and their mechanisms of action in *Panax notoginseng* saponins

Name	Methods	Models	Neurobehavioral effects and Mechanisms
PNS	OFT;SPT	l-DOPA-induced mice; 5-HTP-induced rats	↓ Basal [Ca ²⁺] _i levels; ↓ immobility time; ↑ levels of 5-HT, DA and NE.
Ginsenoside Rb1	EPM test	SPS model and rat model of post-traumatic stress disorder	↓ Anxiety index; ↑ Risk assessment; ↓ grooming behaviors in EPMT; ↑ total number of line crossings of an open field after SPS; ↓ SPS-induced decrease in hypothalamic neuropeptide Y expression; ↑ in locus cerulean tyrosine hydroxylase expression; ↓ expression of BDNF [44, 92].
Ginsenoside Rb1, Re; ginsenoside Rh1, PPD	EPM test	Immobilization stress-induced ICR mice	↑ Time spent in open arms and open arm entries in EPM tests; ↓ Immobilization stress-induced serum levels of corticosterone and IL-6; ↓ anxiolytic effect via γ -aminobutyrate A (GABA _A) receptor(s) [67, 87, 93, 94].
Ginsenoside Rg3	Two electrode voltage-clamp technique	<i>Xenopus laevis</i> frogs	↓ Anxiolytic effect via γ -aminobutyrate A (GABA _A) receptor(s) [87, 94].
Ginsenoside Re	FST; EPM; AAT	Repeated immobilization stress-induced rats	↓ Stress-induced behavioral deficits in these behavioral tests; ↓ TH expression in LC; ↓ mRNA expression of BDNF in the hippocampus; modulate central noradrenergic system in rats [44, 92].
Ginsenoside Rg3 and ginsenoside Rh2	EPM test	Male ICR mice	↑ Time spent on the open arms and the number of open-arm entries; antagonize GABA/benzodiazepines [27, 82].
Ginsenoside Rb1, Rg1, and Ro	EPM test	Male ICR albino mice	↑ Both the frequency and duration of open arm entries [68, 82].
Pseudoginsenoside-F11	Light-dark box test; FST	MA-induced behavioral and neurochemical toxicities in mice	↓ Anxiety-like behavior induced by methamphetamine (MA); ↓ MA-induced prolonged latency; ↓ the error counts; ↓ contents of DOPAC, HVA, and 5-HIAA in the brain of MA-treated mice; antagonize decreases of DA [91].



4. Network Target Analysis









Based on reported researches of each component above, including ginsenoside Rg1, Rg3, Rg5, Rb1, Rb3, Re, Rh1, Rh2, Ro, pseudoginsenoside-F(11), ginsenoside compound K and notoginsenoside R1, network targets of antidepressant, anxiolytic actions or other pharmacological effects were analyzed with network pharmacology tools. In the present work, an integrated in silico approach was introduced to identify the target proteins for the active ingredients of Panax notoginseng (Table 3). Predictive models were used, including STITCH (<http://stitch.embl.de/>) and SwissTargetPrediction (<http://www.swisstargetprediction.ch/>), and databases were mined including Herbal Ingredients' Targets database (<http://lifecenter.sgst.cn/hit/>) [95, 96]. Finally, targets related to antidepressant or anxiolytic effects and other effects were determined, interacting with the selected 12 active ingredients of Panax notoginseng (Figure 1-2).

And main predicted network targets of Panax notoginseng were shown in Table 3 and Figure 1-2. Twenty-six targets were identified for 12 active ingredients of Panax notoginseng with 87 interactions. Multiple therapeutic targets concerning central nervous system were mediated by the active ingredients of Panax notoginseng, such as BAK1, BCL2, BCL2A1, JUN, MAPK8, NFKB1, TP53 and APAF1. Most of these targets are mainly involved in apoptosis and inflammation of vascular and central neural systems.

Among them, BCL2 suppresses apoptosis in a variety of cell systems including neural cells and factor-dependent lymphohematopoietic, and regulates cell death by controlling the mitochondrial membrane permeability by binding to the apoptosis-activating factor (APAF-1). NF-kappa-B is a pleiotropic transcription factor present in almost all cell types, and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes, such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. TP53 acts as a tumor suppressor in many tumor types, and induces growth arrest or apoptosis depending on the physiological circumstances and cell type, involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. These indicate that PNS may have anti-inflammatory and anti-apoptotic effects, which leads to the preservation of brain nerves, and regulate the activity and secretion of nerve cells, exerting anti-depression and anxiolytic effects, which may provide new directions for further in-depth researches of related mechanisms.


Table 3. Active ingredients of Panax notoginseng saponins

No.	Name	Structure	Canonical SMILES
PNS-1	Ginsenoside Rg1		<chem>CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CC(C4C3(C(C4(C(C)O)C)OC5C(C(C(C(O5)CO)O)O)C)O)OC6C(C(C(C(O6)CO)O)O)O)C</chem>
PNS-2	Ginsenoside Rg3		<chem>CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(C(C4(C(C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(O6)CO)O)O)O)C)O)C</chem>

PNS-3	Ginsenoside Rg5		<chem>CC(=CCC=C(C)C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)C)O)C)C</chem>
PNS-4	Ginsenoside Rb1		<chem>CC(=CCCC(C)C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)O)C)OC7C(C(C(C(O7)CO)C8C(C(C(C(O8)CO)O)O)O)O)O)C</chem>
PNS-5	Ginsenoside Rb3		<chem>CC(=CCCC(C)C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)O)C)OC7C(C(C(C(O7)CO)C8C(C(C(C(O8)O)O)O)O)O)O)C</chem>
PNS-6	Ginsenoside Re		<chem>CC1C(C(C(C(O1)OC2C(C(C(OC2OC3CC4(C(CC(C5C4(CCC5C(C)(CCC=C(C)C)OC6C(C(C(C(O6)CO)O)O)C)O)C7(C3C(C(CC7)O)(C)C)C)CO)O)O)O)O</chem>
PNS-7	Ginsenoside Rh1		<chem>CC(=CCCC(C)C1CCC2(C1C(CC3C2(CC(C4C3(CCC(C4(C)C)O)OC5C(C(C(C(O5)CO)O)O)O)C)O)C</chem>
PNS-8	Ginsenoside Rh2		<chem>CC(=CCCC(C)C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)O)C)O)C)O)C</chem>
PNS-9	Pseudoginsenoside-F11		<chem>CC1C(C(C(C(O1)OC2C(C(C(OC2OC3CC4(C(CC(C5C4(CCC5C6(CCC(O6)C(C)C)O)C)O)C7(C3C(C(CC7)O)(C)C)C)CO)O)O)O)O)O</chem>
PNS-10	Ginsenoside Ro		<chem>CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)OC6C(C(C(C(O6)C(=O)O)O)O)OC7C(C(C(C(O7)CO)O)O)O)C)C2C1)C)C(=O)OC8C(C(C(C(O8)CO)O)O)O)C</chem>
PNS-11	Ginsenoside compound K		<chem>CC(=CCCC(C)C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)O)C)O)OC5C(C(C(C(O5)CO)O)O)O)C</chem>

PNS-12

Notoginsenoside R1


CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CC(C4C3(CCC(C4(C)C)O)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(CO6)O)O)C)O)C)OC7C(C(C(C(O7)CO)O)O)C
Table 4. Main predicted target information of *Panax notoginseng*

Node1	Node2	Node1 accession	Node2 accession	Score
APAF1	BAK1	ENSP00000448165	ENSP00000353878	0.997
APAF1	BCL2	ENSP00000448165	ENSP00000329623	0.999
APAF1	BCL2A1	ENSP00000448165	ENSP00000267953	0.912
APAF1	BIK	ENSP00000448165	ENSP00000216115	0.932
APAF1	JUN	ENSP00000448165	ENSP00000360266	0.582
APAF1	MAPK8	ENSP00000448165	ENSP00000353483	0.611
APAF1	MCL1	ENSP00000448165	ENSP00000358022	0.95
APAF1	NFKB1	ENSP00000448165	ENSP00000226574	0.608
APAF1	TP53	ENSP00000448165	ENSP00000269305	0.996
BAK1	APAF1	ENSP00000353878	ENSP00000448165	0.997
BAK1	BBC3	ENSP00000353878	ENSP00000404503	0.414
BAK1	BCL2	ENSP00000353878	ENSP00000329623	0.999
BAK1	BCL2A1	ENSP00000353878	ENSP00000267953	0.987
BAK1	BIK	ENSP00000353878	ENSP00000216115	0.583
BAK1	JUN	ENSP00000353878	ENSP00000360266	0.852
BAK1	JUNB	ENSP00000353878	ENSP00000303315	0.658
BAK1	JUND	ENSP00000353878	ENSP00000252818	0.671
BAK1	MAPK8	ENSP00000353878	ENSP00000353483	0.83
BAK1	MCL1	ENSP00000353878	ENSP00000358022	0.99



Figure 1. Compound-target network of *Panax notoginseng* (Edges represent protein-protein associations; protein-protein interactions are shown in grey, chemical-protein interactions in green and interactions between chemicals in red, and stronger associations are represented by thicker lines. Small nodes: protein of unknown 3D structure; large nodes: some 3D structure is known or predicted; colored nodes: query proteins and first shell of interactors; white nodes: second shell of interactors. And associations are meant to be specific and meaningful, i.e. Proteins jointly contribute to a shared function; this does not necessarily mean they are physically binding each other).




Figure 2. Strong association actions of compound and predicted target network of Panax notoginseng (A represents re-center network or functional domain of compounds associated with BCL2-A1; B represents BCL2 ; C represents TP53; D represents NFKB1)

5. Conclusions

Depression has been becoming the world's fourth-largest disease, and may become the second-largest disease in 2020, second only to cardiac disease. Antidepressants can be divided into 4 categories: tricyclic, tetracyclic, monoamine oxidase inhibitors and other new antidepressants; and sometimes can cause addiction or undesirable side effects. Therefore, new drugs or treatment methods are required. Future studies should consider investigating alternatives to conventional drugs or Chinese medicinal plants. These have been used for more than a thousand years with generally carry a low risk of negative side effects. Panax notoginseng, as traditional Chinese medicine has a long history of high clinical value, such as anti-inflammatory [16, 20, 31, 32], anti-oxidation, inhibition of platelet aggregation, regulation of blood glucose [27, 33, 34] and blood pressure [35-37], inhibition of neuronal apoptosis [14, 38, 39] and neuronal protection. Currently, Panax notoginseng may improve mental function, have anti-insomnia and anti-depression effects, alleviate anxiety, and decrease neural network excitation [25, 26].

As outlined above, we have confirmed that PNS, ginsenoside Rg1, ginsenoside Rb1, ginsenosidenRg3, ginsenoside Rh2, ginsenoside Rg5, compound K and ginsenoside Re have antidepressant or anxiolytic effects, and ginsenoside Rh1 and pseudoginsenoside-F(11) have anxiolytic effects. And these components may exert these effects through regulating neurotransmitter mechanism (5-HT, DA, NE), modulation of the gamma-amino butyric acid (GABA) neurotransmission, glutamatergic system, hypo-thalamus-pituitary-adrenal (HPA) axis, brain-derived neurotrophic factor (BDNF), and its intracellular signaling pathways in the central nervous system; and produce neuronal protection by anti-inflammatory, anti-oxidation, inhibition of neuronal apoptosis or platelet aggregation and its intracellular signaling pathways.

Although among them some compounds have been only proved to have antidepressant or anxiolytic effects in GTS[97], the main chemical composition of Panax notoginseng is similar to that of ginseng; and at present, less researches have been shown on the role of Panax notoginseng and chemical composition in anti-anxiety and anti-depression. Therefore, as a potential new drug, a systematic and in-depth study of the effects and its molecular mechanisms of anti-anxiety and anti-depression of Panax notoginseng is needed.

Further work on elucidation of the structure-function relationship among saponins, understanding of multi-target network pharmacology of Panax notoginseng with Network Pharmacology tools, as well as developing its new clinical usage and comprehensive utilize will enhance the therapeutic potentials of Panax notoginseng. And a clearer understanding of the mechanisms underlying the effects of Panax notoginseng on human cytokine/metabolic systems and on stress-induced hormonal changes could facilitate the development of a wide range of treatments for patients with psychological and physical diseases.

Acknowledgments

This work was supported by the Major Scientific and Technological Special Project for “Significant New Drugs Formulation” (No. 2017ZX09101003-009), the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (No. 2016-I2M-1-012), the CAMS Initiative for Innovative Medicine (No. CAMS-I2M-1-010), the Special Research Project for TCM (No. 201507004), the National Natural Science Foundation of China (No. 81503290), and The National Natural Science Foundation of China (NO. 81773938).

Conflicts of Interest

The authors declare no conflicts of interest.

References

1. Dean, J. and M. Keshavan, *The neurobiology of depression: An integrated view*. Asian J Psychiatr, 2017. **27**: p. 101-111.
2. Dell'Osso, L., et al., *Depression, Serotonin and Tryptophan*. Curr Pharm Des, 2016. **22**(8): p. 949-54.
3. Dunn, E.C., et al., *Genetic determinants of depression: recent findings and future directions*. Harv Rev Psychiatry, 2015. **23**(1): p. 1-18.
4. Hashmi, A.M., Z. Butt, and M. Umair, *Is depression an inflammatory condition? A review of available evidence*. J Pak Med Assoc, 2013. **63**(7): p. 899-906.
5. Catena-Dell'Osso, M., et al., *The relationship between epilepsy and depression: an update*.

- Curr Med Chem, 2013. **20**(23): p. 2861-7.
6. Limon, A., et al., *Targets of polyamine dysregulation in major depression and suicide: Activity-dependent feedback, excitability, and neurotransmission*. *Neurosci Biobehav Rev*, 2016. **66**: p. 80-91.
 7. Novais, F. and S. Starkstein, *Phenomenology of Depression in Alzheimer's Disease*. *J Alzheimers Dis*, 2015. **47**(4): p. 845-55.
 8. Stepanichev, M., et al., *Rodent models of depression: neurotrophic and neuroinflammatory biomarkers*. *Biomed Res Int*, 2014. **2014**: p. 932757.
 9. Uchida, S., et al., *Epigenetic mechanisms of major depression: targeting neuronal plasticity*. *Psychiatry Clin Neurosci*, 2017.
 10. Zheng, X., et al., *Chemical dampening of Ly6C(hi) monocytes in the periphery produces anti-depressant effects in mice*. *Sci Rep*, 2016. **6**: p. 19406.
 11. Zong, S., et al., *Neuronal Surface Autoantibodies in Neuropsychiatric Disorders: Are There Implications for Depression?* *Front Immunol*, 2017. **8**: p. 752.
 12. Chi, S., et al., *Depression in Alzheimer's disease: epidemiology, mechanisms, and management*. *J Alzheimers Dis*, 2014. **42**(3): p. 739-55.
 13. Flaster, M., A. Sharma, and M. Rao, *Poststroke depression: a review emphasizing the role of prophylactic treatment and synergy with treatment for motor recovery*. *Top Stroke Rehabil*, 2013. **20**(2): p. 139-50.
 14. Li, W., et al., *Systematic hypothesis for post-stroke depression caused inflammation and neurotransmission and resultant on possible treatments*. *Neuro Endocrinol Lett*, 2014. **35**(2): p. 104-9.
 15. Benson, C., et al., *Biogenic Amines and the Amino Acids GABA and Glutamate: Relationships with Pain and Depression*. *Mod Trends Pharmacopsychiatry*, 2015. **30**: p. 67-79.
 16. Jeon, S.W. and Y.K. Kim, *Neuroinflammation and cytokine abnormality in major depression: Cause or consequence in that illness?* *World J Psychiatry*, 2016. **6**(3): p. 283-93.
 17. Oakes, P., et al., *The neuroanatomy of depression: A review*. *Clin Anat*, 2017. **30**(1): p. 44-49.
 18. Lin, F.B., D.R. Hou, and Q.P. Tang, *[Research progress of depression and the application of esketamine]*. *Nan Fang Yi Ke Da Xue Xue Bao*, 2016. **37**(4): p. 567-inside back cover.
 19. Zhang, H., et al., *Ginsenoside Rg3 exerts anti-depressive effect on an NMDA-treated cell model and a chronic mild stress animal model*. *J Pharmacol Sci*, 2017. **134**(1): p. 45-54.
 20. Allison, D.J. and D.S. Ditor, *The common inflammatory etiology of depression and cognitive impairment: a therapeutic target*. *J Neuroinflammation*, 2014. **11**: p. 151.
 21. Anderson, G. and M. Maes, *Neurodegeneration in Parkinson's disease: interactions of oxidative stress, tryptophan catabolites and depression with mitochondria and sirtuins*. *Mol Neurobiol*, 2014. **49**(2): p. 771-83.
 22. Anderson, G. and M. Maes, *TRYCAT pathways link peripheral inflammation, nicotine, somatization and depression in the etiology and course of Parkinson's disease*. *CNS Neurol Disord Drug Targets*, 2014. **13**(1): p. 137-49.
 23. Anderson, G., et al., *Gut Permeability and Microbiota in Parkinson's Disease: Role of Depression, Tryptophan Catabolites, Oxidative and Nitrosative Stress and Melatonergic Pathways*. *Curr Pharm Des*, 2016. **22**(40): p. 6142-6151.
 24. Braga, J. and A. Campar, *[Biological causes of depression in Systemic Lupus Erythematosus]*. *Acta Reumatol Port*, 2014. **39**(3): p. 218-26.

25. Cui, J., L. Jiang, and H. Xiang, *Ginsenoside Rb3 exerts antidepressant-like effects in several animal models*. *J Psychopharmacol*, 2012. **26**(5): p. 697-713.
26. Xiang, H., et al., *The antidepressant effects and mechanism of action of total saponins from the caudexes and leaves of Panax notoginseng in animal models of depression*. *Phytomedicine*, 2011. **18**(8-9): p. 731-8.
27. Zhang, H., et al., *Antidepressant-like effects of ginsenosides: A comparison of ginsenoside Rb3 and its four deglycosylated derivatives, Rg3, Rh2, compound K, and 20(S)-protopanaxadiol in mice models of despair*. *Pharmacol Biochem Behav*, 2016. **140**: p. 17-26.
28. Su, P., et al., *[Advance in studies of Panax notoginseng saponins on pharmacological mechanism of nervous system disease]*. *Zhongguo Zhong Yao Za Zhi*, 2014. **39**(23): p. 4516-21.
29. Bahramsoltani, R., et al., *Phytochemical constituents as future antidepressants: a comprehensive review*. *Rev Neurosci*, 2015. **26**(6): p. 699-719.
30. Wang, T., et al., *Traditional uses, botany, phytochemistry, pharmacology and toxicology of Panax notoginseng (Burk.) F.H. Chen: A review*. *J Ethnopharmacol*, 2016. **188**: p. 234-58.
31. Zhang, J., et al., *Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activation*. *J Pharmacol Exp Ther*, 2015. **352**(2): p. 315-24.
32. Zheng, X., et al., *Peripheral immunomodulation with ginsenoside Rg1 ameliorates neuroinflammation-induced behavioral deficits in rats*. *Neuroscience*, 2014. **256**: p. 210-22.
33. Kim, N.H., et al., *Antidepressant-like effect of altered Korean red ginseng in mice*. *Behav Med*, 2011. **37**(2): p. 42-6.
34. Xie, T., et al., *[Metabolomics analysis of Tripterygium wilfordii formulation based on theory of detoxicity compatibility]*. *Zhongguo Zhong Yao Za Zhi*, 2016. **41**(6): p. 1124-1129.
35. Pang, H.H., et al., *Effect of compatible herbs on the pharmacokinetics of effective components of Panax notoginseng in Fufang Xueshuantong Capsule*. *J Zhejiang Univ Sci B*, 2017. **18**(4): p. 343-352.
36. Tian, Z., et al., *Effect of Panax notoginseng saponins on the pharmacokinetics of aspirin in rats*. *J Chromatogr B Analyt Technol Biomed Life Sci*, 2017. **1040**: p. 136-143.
37. Zhao, S., et al., *Effect of panax notoginseng saponins injection on the p38MAPK pathway in lung tissue in a rat model of hypoxic pulmonary hypertension*. *Chin J Integr Med*, 2015. **21**(2): p. 147-51.
38. Hou, Q.L., et al., *[Protective effect of notoginsenoside R1 on neuron injury induced by OGD/R through ATF6/Akt signaling pathway]*. *Zhongguo Zhong Yao Za Zhi*, 2017. **42**(6): p. 1167-1174.
39. Yang, X., et al., *Panax Notoginseng Saponins attenuates sevoflurane-induced nerve cell injury by modulating AKT signaling pathway*. *Mol Med Rep*, 2017. **16**(5): p. 7829-7834.
40. Oh, H.A., et al., *Anti-stress Effects of 20(S)-Protopanaxadiol and 20(S)-Protopanaxatriol in Immobilized Mice*. *Biological & Pharmaceutical Bulletin*, 2015. **38**(2): p. 331-335.
41. Albert, P.R. and L.M. Fiori, *Transcriptional dys-regulation in anxiety and major depression: 5-HT1A gene promoter architecture as a therapeutic opportunity*. *Curr Pharm Des*, 2014. **20**(23): p. 3738-50.
42. Liu, M.Y., L.J. Zhang, and M.C. Liu, *[Effect of ginsenoside pre-treatment on 5-hydroxytryptamine system in SD rats with myocardial infarction and depression]*. *Zhonghua Nei Ke Za Zhi*, 2016. **55**(9): p. 700-4.

43. Jiang, B., et al., *Antidepressant-like effects of ginsenoside Rg1 are due to activation of the BDNF signalling pathway and neurogenesis in the hippocampus*. *Br J Pharmacol*, 2012. **166**(6): p. 1872-87.
44. Lee, B., et al., *Effect of ginsenoside Re on depression- and anxiety-like behaviors and cognition memory deficit induced by repeated immobilization in rats*. *J Microbiol Biotechnol*, 2012. **22**(5): p. 708-20.
45. Liu, Z., et al., *The effects of ginsenoside Rg1 on chronic stress induced depression-like behaviors, BDNF expression and the phosphorylation of PKA and CREB in rats*. *Neuroscience*, 2016. **322**: p. 358-69.
46. Si, Y., et al., *Effects of Panax notoginseng saponins on proliferation and differentiation of rat embryonic cortical neural stem cells*. *J Chin Med Assoc*, 2016. **79**(5): p. 256-63.
47. Zhao, M., et al., *BDNF Val66Met polymorphism, life stress and depression: A meta-analysis of gene-environment interaction*. *J Affect Disord*, 2017. **227**: p. 226-235.
48. Anderson, G., et al., *Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications*. *CNS Drugs*, 2014. **28**(1): p. 1-10.
49. Anderson, G., M. Maes, and M. Berk, *Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways*. *Prog Neuropsychopharmacol Biol Psychiatry*, 2013. **42**: p. 101-14.
50. Choi, J.G., et al., *Protective Effect of Panax notoginseng Root Water Extract against Influenza A Virus Infection by Enhancing Antiviral Interferon-Mediated Immune Responses and Natural Killer Cell Activity*. *Front Immunol*, 2017. **8**: p. 1542.
51. Han, J.Y., et al., *Effects and mechanisms of compound Chinese medicine and major ingredients on microcirculatory dysfunction and organ injury induced by ischemia/reperfusion*. *Pharmacol Ther*, 2017. **177**: p. 146-173.
52. Kang, A., et al., *Peripheral anti-inflammatory effects explain the ginsenosides paradox between poor brain distribution and anti-depression efficacy*. *J Neuroinflammation*, 2011. **8**: p. 100.
53. Kang, A., et al., *Suppressive Effect of Ginsenoside Rg3 against Lipopolysaccharide-Induced Depression-Like Behavior and Neuroinflammation in Mice*. *J Agric Food Chem*, 2017. **65**(32): p. 6861-6869.
54. Pan, L., et al., *Panax Notoginseng Saponins Ameliorates Coxsackievirus B3-Induced Myocarditis by Activating the Cystathionine-gamma-Lyase/Hydrogen Sulfide Pathway*. *J Cardiovasc Transl Res*, 2015. **8**(9): p. 536-44.
55. Wang, J., et al., *Qishenyiqi Dropping Pill attenuates myocardial fibrosis in rats by inhibiting RAAS-mediated arachidonic acid inflammation*. *J Ethnopharmacol*, 2015. **176**: p. 375-84.
56. Wenxi, D., et al., *Panax notoginseng saponins suppress radiation-induced osteoporosis by regulating bone formation and resorption*. *Phytomedicine*, 2015. **22**(9): p. 813-9.
57. Wu, J.X. and J.X. Chen, *[Negative chronotropic and inotropic effects of Panax notoginseng saponins]*. *Zhongguo Yao Li Xue Bao*, 1988. **9**(5): p. 409-12.
58. Ge, Z.R., et al., *Cardioprotective effect of notoginsenoside R1 in a rabbit lung remote ischemic postconditioning model via activation of the TGF-beta1/TAK1 signaling pathway*. *Exp Ther Med*, 2016. **11**(6): p. 2341-2348.

59. Wang, T., et al., *Notoginsenoside R1 stimulates osteogenic function in primary osteoblasts via estrogen receptor signaling*. *Biochem Biophys Res Commun*, 2015. **466**(2): p. 232-9.
60. Wang, Y., et al., *Endothelium-dependent vasodilation effects of Panax notoginseng and its main components are mediated by nitric oxide and cyclooxygenase pathways*. *Exp Ther Med*, 2016. **12**(6): p. 3998-4006.
61. Xu, Y., et al., *Notoginsenoside R1 attenuates hypoxia and hypercapnia-induced vasoconstriction in isolated rat pulmonary arterial rings by reducing the expression of ERK*. *Am J Chin Med*, 2014. **42**(4): p. 799-816.
62. Luo, J., et al., *Propofol interacts with stimulus intensities of electroconvulsive shock to regulate behavior and hippocampal BDNF in a rat model of depression*. *Psychiatry Res*, 2012. **198**(2): p. 300-6.
63. Gazal, M., et al., *Antidepressant-like effects of aqueous extract from Cecropia pachystachya leaves in a mouse model of chronic unpredictable stress*. *Brain Res Bull*, 2014. **108**: p. 10-7.
64. Pechlivanova, D., et al., *Dose-dependent effects of caffeine on behavior and thermoregulation in a chronic unpredictable stress model of depression in rats*. *Behav Brain Res*, 2010. **209**(2): p. 205-11.
65. Taksande, B.G., et al., *Agmatine attenuates chronic unpredictable mild stress induced behavioral alteration in mice*. *Eur J Pharmacol*, 2013. **720**(1-3): p. 115-20.
66. Shi, M., J.Y. Wang, and F. Luo, *Depression shows divergent effects on evoked and spontaneous pain behaviors in rats*. *J Pain*, 2010. **11**(3): p. 219-29.
67. Wu, H.F., C.H. Zhu, and J.Y. Guo, *[Effect of ginsenoside Rg1 on behaviors and hippocampal amino acids in depressive-like rats]*. *Zhongguo Zhong Yao Za Zhi*, 2012. **37**(20): p. 3117-21.
68. Carr, M.N., N. Bekku, and H. Yoshimura, *Identification of anxiolytic ingredients in ginseng root using the elevated plus-maze test in mice*. *Eur J Pharmacol*, 2006. **531**(1-3): p. 160-5.
69. Cha, H.Y., et al., *Anxiolytic-like effects of ginsenosides on the elevated plus-maze model in mice*. *Biol Pharm Bull*, 2005. **28**(9): p. 1621-5.
70. Huang, X.P., et al., *Effects of the Combination of the Main Active Components of Astragalus and Panax notoginseng on Inflammation and Apoptosis of Nerve Cell after Cerebral Ischemia-Reperfusion*. *Am J Chin Med*, 2015. **43**(7): p. 1419-38.
71. Oh, H.A., et al., *Anti-stress effects of 20(S)-protopanaxadiol and 20(S)-protopanaxatriol in immobilized mice*. *Biol Pharm Bull*, 2015. **38**(2): p. 331-5.
72. Huang, X.P., et al., *Effects of the main active components combinations of Astragalus and Panax notoginseng on energy metabolism in brain tissues after cerebral ischemia-reperfusion in mice*. *Pharmacogn Mag*, 2015. **11**(44): p. 732-9.
73. Qi, H., et al., *Anti-platelet activity of panaxatriol saponins is mediated by suppression of intracellular calcium mobilization and ERK2/p38 activation*. *BMC Complement Altern Med*, 2016. **16**: p. 174.
74. Li, Q., et al., *[Influences of Panax notoginsenosid on spontaneous contraction of small intestine smooth muscle of rabbits in vitro]*. *Zhongguo Ying Yong Sheng Li Xue Za Zhi*, 2010. **26**(1): p. 117-20.
75. You, Z., et al., *Antidepressant-like effects of ginsenoside Rg3 in mice via activation of the hippocampal BDNF signaling cascade*. *J Nat Med*, 2017. **71**(2): p. 367-379.
76. Leff-Gelman, P., et al., *The Immune System and the Role of Inflammation in Perinatal Depression*. *Neurosci Bull*, 2016. **32**(4): p. 398-420.

77. Wang, J., et al., *Protective effects of geniposide and ginsenoside Rg1 combination treatment on rats following cerebral ischemia are mediated via microglial microRNA1555p inhibition*. *Mol Med Rep*, 2018. **17**(2): p. 3186-3193.
78. Xu, C., et al., *20(S)-protopanaxadiol, an active ginseng metabolite, exhibits strong antidepressant-like effects in animal tests*. *Prog Neuropsychopharmacol Biol Psychiatry*, 2010. **34**(8): p. 1402-11.
79. Yin, S., et al., *Effects of notoginsenoside R1 on CYP1A2, CYP2C11, CYP2D1, and CYP3A1/2 activities in rats by cocktail probe drugs*. *Pharm Biol*, 2016. **54**(2): p. 231-6.
80. Shi, X., et al., *Panax notoginseng saponins provide neuroprotection by regulating NgR1/RhoA/ROCK2 pathway expression, in vitro and in vivo*. *J Ethnopharmacol*, 2016. **190**: p. 301-12.
81. Yamada, N., H. Araki, and H. Yoshimura, *Identification of antidepressant-like ingredients in ginseng root (Panax ginseng C.A. Meyer) using a menopausal depressive-like state in female mice: participation of 5-HT2A receptors*. *Psychopharmacology (Berl)*, 2011. **216**(4): p. 589-99.
82. Kim, T.W., et al., *Anxiolytic-like effects of ginsenosides Rg3 and Rh2 from red ginseng in the elevated plus-maze model*. *Planta Med*, 2009. **75**(8): p. 836-9.
83. Xu, D., et al., *Antidepressant-like effects of ginsenoside Rg5 in mice: Involving of hippocampus BDNF signaling pathway*. *Neurosci Lett*, 2017. **645**: p. 97-105.
84. Ducottet, C., A. Aubert, and C. Belzung, *Susceptibility to subchronic unpredictable stress is related to individual reactivity to threat stimuli in mice*. *Behav Brain Res*, 2004. **155**(2): p. 291-9.
85. Jin, C., et al., *Ginsenoside Rg1-induced antidepressant effects involve the protection of astrocyte gap junctions within the prefrontal cortex*. *Prog Neuropsychopharmacol Biol Psychiatry*, 2017. **75**: p. 183-191.
86. Zhang, C., et al., *Hormetic effect of panaxatriol saponins confers neuroprotection in PC12 cells and zebrafish through PI3K/AKT/mTOR and AMPK/SIRT1/FOXO3 pathways*. *Sci Rep*, 2017. **7**: p. 41082.
87. Jiang, S., et al., *Inactivation of GABA(A) receptor reduces ginsenoside Rb3 neuroprotection in mouse hippocampal slices after oxygen-glucose deprivation*. *J Ethnopharmacol*, 2011. **133**(2): p. 914-6.
88. Cheong, J.H., et al., *Anxiolytic and Antidepressant Activities of Ginsenoside Rb1*. *Biomolecules & Therapeutics*, 2007. **15**(1): p. 27-33.
89. Churchill, J.D., et al., *The nootropic properties of ginseng saponin Rb1 are linked to effects on anxiety*. *Integr Physiol Behav Sci*, 2002. **37**(3): p. 178-87.
90. Wang, Z.J., et al., *Induction of differentiation by panaxydol in human hepatocarcinoma SMMC-7721 cells via cAMP and MAP kinase dependent mechanism*. *Yakugaku Zasshi*, 2011. **131**(6): p. 993-1000.
91. Wu, C.F., et al., *Protective effects of pseudoginsenoside-F11 on methamphetamine-induced neurotoxicity in mice*. *Pharmacol Biochem Behav*, 2003. **76**(1): p. 103-9.
92. Lee, B., et al., *Ginsenoside Rb1 rescues anxiety-like responses in a rat model of post-traumatic stress disorder*. *J Nat Med*, 2016. **70**(2): p. 133-44.
93. Gordon, J.L., et al., *Ovarian hormone fluctuation, neurosteroids, and HPA axis dysregulation in perimenopausal depression: a novel heuristic model*. *Am J Psychiatry*, 2015. **172**(3): p.

- 227-36.
94. Lee, B.-H., et al., *Ginsenoside Rg(3) regulates GABA(A) receptor channel activity: Involvement of interaction with the gamma(2) subunit*. *European Journal of Pharmacology*, 2013. **705**(1-3): p. 119-125.
 95. Yue, S.-J., et al., *Herb pair Danggui-Honghua: mechanisms underlying blood stasis syndrome by system pharmacology approach*. *Scientific Reports*, 2017. **7**: p. 40318.
 96. Li, J., et al., *Systems pharmacology-based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronic obstructive pulmonary disease*. *Scientific Reports*, 2015. **5**(1) : p. 1-15.
 97. Lee, S. and D.K. Rhee, *Effects of ginseng on stress-related depression, anxiety, and the hypothalamic-pituitary-adrenal axis*. *J Ginseng Res*, 2017. **41**(4): p. 589-594.